New review links higher nut intake with lower hypertension risk
A dose–response analysis of prospective studies found lower risk at higher nut intake, with “probable” likelihood of causality by WCRF criteria.
High evidenceReview
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
In this updated analysis, the authors searched PubMed and Embase for prospective cohort studies published in English up to April 4, 2026. They included eight studies with a total of 20,665 cases and extracted adjusted risk estimates for the relationship between nut consumption and hypertension.
Overall, the meta-analysis reported lower hypertension risk with higher nut intake. The authors also assessed bias and evidence strength using WCRF criteria and graded the likelihood of causality as “probable.” Some nonlinear patterns and between-study differences were noted, which the authors considered in interpreting the results.
The question reviewed
The researchers examined whether nut consumption is associated with the risk of developing hypertension. They used a systematic review and dose–response meta-analysis of prospective cohort studies, including studies that reported adjusted relative risk estimates (published in English) and were found via PubMed and Embase searches up to 4 April 2026. The meta-analysis included eight studies (20,665 cases, with the abstract listing “x” for the remaining figure as unknown).
Key conclusions
Across included prospective studies, the summary relative risk (RR) for the highest versus lowest category of nut intake was 0.84 (95% CI: 0.77–0.91), with I² = 50% and p heterogeneity = 0.05. For the dose–response comparison, the RR per 28 g/day was 0.80 (95% CI: 0.71–0.89), with I² = 75% and p heterogeneity < 0.0001. The authors reported no indication of publication bias using Begg’s test (p = 0.71), Egger’s test (p = 0.10), or funnel plot inspection. They noted some indication of nonlinearity (p nonlinearity = 0.07), and described a 26% reduction in risk for 30 g/day versus 0 g/day. Using WCRF criteria, they graded the likelihood of causality as “probable.”
Who this is relevant to
These findings may be most applicable to people in populations similar to those studied in the included English-language prospective cohort studies that measured nut intake and assessed hypertension risk. They do not directly establish that increasing nut intake will cause lower hypertension risk for any specific person, because observational studies cannot fully rule out other factors. This work is not a clinical trial and does not provide personalized guidance; it only summarizes associations reported across multiple studies.
What this could mean
Hypertension is a common health condition, so evidence about dietary factors associated with its risk is of broad public interest. This study is a review of prospective human data, so it is more directly relevant to general human health than animal or lab findings. Even so, because the included studies are observational, the results reflect an association rather than proof that nut intake directly causes lower hypertension risk in individuals.
Limitations & evidence assessment
The analysis is based on prospective cohort studies, which can still be affected by confounding and measurement differences in how nut intake and hypertension were assessed. The abstract does not provide key details about populations, follow-up duration, how nut intake categories were defined, or which nut types were included, limiting how precisely readers can interpret the dose–response relationship. There was moderate to high heterogeneity (I² up to 75%), suggesting results varied across studies. The abstract notes some indication of nonlinearity and does not fully characterize its practical meaning. The abstract also contains an incomplete numeric detail (“x”) for included studies, so the full context of the included-case reporting is unclear from the provided text.
Why this evidence level: Meta-analysis pooling multiple studies sits at the top of common evidence hierarchies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
British Journal Of Nutrition · 2026 · DOI: 10.1017/s0007114526108137
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
